(Q44712966)

5 December 2017

title

Time course of clinical response to venlafaxine: relevance of plasma level and chirality (English)

1 reference

5 December 2017

1 reference

6

1 reference

5 December 2017

4

Serge Rudaz

1 reference

5 December 2017

5

Jean-Luc Veuthey

1 reference

5 December 2017

1

Marianne Gex-Fabry

1 reference

Androniki E Balant-Gorgia

5 December 2017

series ordinal

2

object named as

Androniki E Balant-Gorgia

1 reference

5 December 2017

3

Luc P Balant

1 reference

5 December 2017

publication date

24 December 2003

1 reference

European Journal of Clinical Pharmacology

5 December 2017

published in

1 reference

5 December 2017

volume

59

1 reference

5 December 2017

issue

12

1 reference

5 December 2017

page(s)

883-891

1 reference

Venlafaxine: measuring the onset of antidepressant action

5 December 2017

cites work

1 reference

12 December 2020

Lithium augmentation in venlafaxine non-responders: an open study

1 reference

12 December 2020

Antidepressant drug selection: criteria and options.

1 reference

12 December 2020

Lithium augmentation of venlafaxine: an open-label trial

1 reference

12 December 2020

Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability

1 reference

12 December 2020

Evidence of the dual mechanisms of action of venlafaxine

1 reference

12 December 2020

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

1 reference

12 December 2020

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

12 December 2020

Comparing onset of effect of antidepressants: Pragmatic considerations on methods and end-points

1 reference

12 December 2020

Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins

1 reference

12 December 2020

Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants.

1 reference

12 December 2020

Do some antidepressants work faster than others?

1 reference

12 December 2020

Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study

1 reference

12 December 2020

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

1 reference

12 December 2020

Identification of true drug response to antidepressants. Use of pattern analysis

1 reference

12 December 2020

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

12 December 2020

Characterizing onset in psychopharmacological clinical trials

1 reference

12 December 2020

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans

1 reference

12 December 2020

Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients

1 reference

12 December 2020

Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data.

1 reference

12 December 2020

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

1 reference

12 December 2020

Neuropharmacology of venlafaxine

1 reference

12 December 2020

Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials

1 reference

12 December 2020

Sustained response to open-label venlafaxine in drug-resistant major depression

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related?

1 reference

12 December 2020

Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.

1 reference

12 December 2020

Further evidence that a placebo response to antidepressants can be identified

1 reference

12 December 2020

Dose-response relationship with venlafaxine

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

12 December 2020

Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

An ideal trial to test differential onset of antidepressant effect

1 reference

12 December 2020

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

1 reference

12 December 2020

MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors.

1 reference

12 December 2020

Venlafaxine serum levels and CYP2D6 genotype

1 reference

12 December 2020

Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs

1 reference

12 December 2020

The pharmacology of putative early-onset antidepressant strategies

1 reference

12 December 2020

Antidepressant treatment of the depressed patient with insomnia.

1 reference

12 December 2020

Duration of antidepressant trials: clinical and research implications

1 reference

12 December 2020

Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia

1 reference

12 December 2020

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

12 December 2020

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

12 December 2020

Dual monoamine modulation for improved treatment of major depressive disorder

1 reference

12 December 2020

10.1007/S00228-003-0710-3

Identifiers

DOI

1 reference

5 December 2017

1 reference